VIR-2703 (ALN-COV) Description
VIR-2703 is an investigational RNAi therapeutic which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).
Vir Biotechnology and Alnylam Pharmaceuticals partnership announced the expansion of their existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases.
The partnership was recently expanded to include SARS-CoV-2, the virus behind the novel coronavirus infection.
The partners plan to advance the investigational RNAi therapeutic as an inhalational formulation for the potential treatment and/or prevention of novel coronavirus.
According to the partners, multiple highly potent siRNAs were identified that showed a three-log reduction of viral replication in an in vitro SARS-CoV-2 live virus model conducted by Vir Biotechnology.
VIR-2703 (ALN-COV) Indication
VIR-2703 (ALN-COV) is indicated for potential treatment and/or prevention of COVID-19.
VIR-2703 (ALN-COV) Dosage
VIR-2703 was shown to have an effective concentration for 50% inhibition (EC50) of less than 100 picomolar and an EC95 of less than 1 nanomolar in the SARS-CoV-2 live virus model measuring inhibition of infectious virion production.
VIR-2703 also showed predicted reactivity against greater than 99.9% of the over 4,300 SARS-CoV-2 genomes currently available in public databases that meet analysis requirements, the companies added and was also predicted to have reactivity toward the SARS-CoV genome.
VIR-2701 (ALN-COV) News
March 4, 2020 - Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19
April 2, 2020 - Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. today announced an expansion to their broad multi-target existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases, including SARS-CoV-2, the virus that causes the disease COVID-19.
May 4, 2020 - Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19